These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30431426)

  • 1. Bioequivalence of fluticasone propionate and salmeterol (FS) given by the FS Spiromax® and Seretide Accuhaler® systems
.
    Wayne D; Iverson H; Gillespie M; Hellriegel E; Small C
    Int J Clin Pharmacol Ther; 2019 Jan; 57(1):43-54. PubMed ID: 30431426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.
    Kirjavainen M; Mattila L; Vahteristo M; Korhonen J; Lähelmä S
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):290-297. PubMed ID: 29493402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
    Nugent C; Yiu G; Song S; Caracta C
    J Asthma; 2018 Aug; 55(8):898-906. PubMed ID: 28933971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of budesonide plus formoterol (BF) Spiromax® and BF Turbohaler® (with and without charcoal block) in healthy volunteers.
    Weisfeld L; Shu Y; Shah TP
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):593-602. PubMed ID: 26042485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus(®) in Healthy Adults.
    Vutikullird AB; Gillespie M; Song S; Steinfeld J
    J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):207-14. PubMed ID: 26624976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies.
    Haughie S; Allan R; Wood N; Ward J
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):34-42. PubMed ID: 31364911
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
    Li S; Feng K; Lee J; Gong Y; Wu F; Newman B; Yoon M; Fang L; Zhao L; Gobburu JVS
    AAPS J; 2024 Apr; 26(3):56. PubMed ID: 38671158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma.
    Miller DS; Yiu G; Hellriegel ET; Steinfeld J
    Allergy Asthma Proc; 2016 Jul; 37(4):291-301. PubMed ID: 27216137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plume Characteristics of Two HFA-Driven Inhaled Corticosteroid/Long-Acting Beta2-Agonist Combination Pressurized Metered-Dose Inhalers.
    Johal B; Murphy S; Tuohy J; Marshall J
    Adv Ther; 2015 Jun; 32(6):567-79. PubMed ID: 26100350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Exposures of Fluticasone Propionate and Salmeterol Following Inhalation via Metered Dose Inhaler with the Mini Spacer Compared with the Aerochamber Plus Spacer.
    Mehta R; Montembault M; Warren F; Gupta A; Brealey N; Moore A
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):386-92. PubMed ID: 26824933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study.
    Nathan RA; Rooklin A; Schoaf L; Scott C; Ellsworth A; House K; Dorinsky P
    Clin Ther; 2006 Jan; 28(1):73-85. PubMed ID: 16490581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
    Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
    Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized Comparison of the Pharmacokinetics and Bioavailability of Fluticasone Propionate Delivered via Xhance Exhalation Delivery System Versus Flonase Nasal Spray and Flovent HFA Inhalational Aerosol.
    Messina JC; Offman E; Carothers JL; Mahmoud RA
    Clin Ther; 2019 Nov; 41(11):2343-2356. PubMed ID: 31732149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
    Hochhaus G; Chen MJ; Kurumaddali A; Schilling U; Jiao Y; Drescher SK; Amini E; Berger SM; Kandala B; Tabulov C; Shao J; Seay B; Abu-Hasan MN; Baumstein SM; Winner L; Shur J; Price R; Hindle M; Wei X; Carrasco C; Sandell D; Oguntimein O; Kinjo M; Delvadia R; Saluja B; Lee SL; Conti DS; Bulitta JB
    AAPS J; 2021 Mar; 23(3):48. PubMed ID: 33768368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the Pharmacokinetics of Salmeterol and Fluticasone Propionate 50/100 µg Delivered in Combination as a Dry Powder Via a Capsule-Based Inhaler and a Multi-Dose Inhaler.
    Mehta R; Riddell K; Gupta A; Louey MD; Chan RH
    Clin Drug Investig; 2015 May; 35(5):319-26. PubMed ID: 25805608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.
    Chapman KR; Ringdal N; Backer V; Palmqvist M; Saarelainen S; Briggs M
    Can Respir J; 1999; 6(1):45-51. PubMed ID: 10202220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of fluticasone propionate/salmeterol using two different dry powder inhalers.
    Soulele K; Macheras P; Silvestro L; Rizea Savu S; Karalis V
    Eur J Pharm Sci; 2015 Dec; 80():33-42. PubMed ID: 26296862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers.
    Horhota ST; van Noord JA; Verkleij CB; Bour LJ; Sharma A; Trunk M; Cornelissen PJ
    AAPS J; 2015 Jul; 17(4):871-80. PubMed ID: 25794622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.